CN103874485B - 氧化的磷脂的制剂和剂型 - Google Patents

氧化的磷脂的制剂和剂型 Download PDF

Info

Publication number
CN103874485B
CN103874485B CN201280049926.9A CN201280049926A CN103874485B CN 103874485 B CN103874485 B CN 103874485B CN 201280049926 A CN201280049926 A CN 201280049926A CN 103874485 B CN103874485 B CN 103874485B
Authority
CN
China
Prior art keywords
agent
liquid filled
filled capsule
weight
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280049926.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103874485A (zh
Inventor
N·谢尔
V·M·扬
A·麦克诺顿
M·巴赫沙依
I·R·怀尔丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of CN103874485A publication Critical patent/CN103874485A/zh
Application granted granted Critical
Publication of CN103874485B publication Critical patent/CN103874485B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
CN201280049926.9A 2011-09-01 2012-08-31 氧化的磷脂的制剂和剂型 Expired - Fee Related CN103874485B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529989P 2011-09-01 2011-09-01
US61/529,989 2011-09-01
PCT/US2012/053533 WO2013033642A1 (en) 2011-09-01 2012-08-31 Formulations and dosage forms of oxidized phospholipids

Publications (2)

Publication Number Publication Date
CN103874485A CN103874485A (zh) 2014-06-18
CN103874485B true CN103874485B (zh) 2017-06-09

Family

ID=46964020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049926.9A Expired - Fee Related CN103874485B (zh) 2011-09-01 2012-08-31 氧化的磷脂的制剂和剂型

Country Status (15)

Country Link
US (3) US9254297B2 (cg-RX-API-DMAC7.html)
EP (1) EP2750668B1 (cg-RX-API-DMAC7.html)
JP (1) JP6109175B2 (cg-RX-API-DMAC7.html)
KR (1) KR101939430B1 (cg-RX-API-DMAC7.html)
CN (1) CN103874485B (cg-RX-API-DMAC7.html)
AU (1) AU2012301602B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004916B1 (cg-RX-API-DMAC7.html)
CA (1) CA2847218C (cg-RX-API-DMAC7.html)
EA (1) EA029274B1 (cg-RX-API-DMAC7.html)
ES (1) ES2768266T3 (cg-RX-API-DMAC7.html)
IL (1) IL231222B (cg-RX-API-DMAC7.html)
MX (1) MX357759B (cg-RX-API-DMAC7.html)
SG (1) SG11201400208PA (cg-RX-API-DMAC7.html)
WO (1) WO2013033642A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401478B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI927968B (zh) 2020-09-08 2026-06-11 美商建南德克公司 形成混合物的管件套組、形成醫藥組成物或醫藥組成物混合物之系統、使用蠕動泵轉移醫藥組成物之方法、製造包含核酸及一種或多種脂質之醫藥組成物之方法,以及用於流體泵之脈動阻尼器

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
SG11201400208PA (en) * 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
US10597603B2 (en) 2014-12-16 2020-03-24 Polymer Ventures, Inc. Oil recovery aid
PY1576960A (es) * 2014-12-16 2017-12-01 Polymer Ventures Auxiliar de recuperación de aceite
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083469A1 (en) * 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Treatment with vb-201

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
US4970233A (en) * 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
WO2002053092A2 (en) 2001-01-04 2002-07-11 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
NZ553147A (en) 2004-07-09 2010-07-30 Vascular Biogenics Ltd Improved process for the preparation of oxidized phospholipids
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
SG11201400208PA (en) 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083469A1 (en) * 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Treatment with vb-201

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI927968B (zh) 2020-09-08 2026-06-11 美商建南德克公司 形成混合物的管件套組、形成醫藥組成物或醫藥組成物混合物之系統、使用蠕動泵轉移醫藥組成物之方法、製造包含核酸及一種或多種脂質之醫藥組成物之方法,以及用於流體泵之脈動阻尼器

Also Published As

Publication number Publication date
EA029274B1 (ru) 2018-03-30
WO2013033642A1 (en) 2013-03-07
EP2750668A1 (en) 2014-07-09
KR20140078641A (ko) 2014-06-25
ES2768266T3 (es) 2020-06-22
IL231222B (en) 2018-01-31
EP2750668B1 (en) 2019-12-11
AU2012301602A1 (en) 2013-05-02
MX357759B (es) 2018-07-24
MX2014002362A (es) 2014-04-30
BR112014004916B1 (pt) 2021-12-21
US20160220590A1 (en) 2016-08-04
HK1198430A1 (en) 2015-04-24
SG11201400208PA (en) 2014-03-28
AU2012301602B2 (en) 2015-09-03
IL231222A0 (en) 2014-04-30
CA2847218A1 (en) 2013-03-07
CA2847218C (en) 2018-02-27
US20130209555A1 (en) 2013-08-15
NZ621710A (en) 2015-10-30
ZA201401478B (en) 2016-09-28
KR101939430B1 (ko) 2019-01-16
JP2014525463A (ja) 2014-09-29
EA201490544A1 (ru) 2014-08-29
JP6109175B2 (ja) 2017-04-05
CN103874485A (zh) 2014-06-18
BR112014004916A2 (pt) 2017-04-04
US9254297B2 (en) 2016-02-09
US20190008880A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
EP2750668B1 (en) Formulations and dosage forms of oxidized phospholipids
KR101813728B1 (ko) 결정화 방법 및 생체이용률
JP7542309B2 (ja) 多孔性賦形剤を含む経鼻用医薬組成物
ES2731881T3 (es) Composiciones que comprenden compuestos activos lipófilos y método para su preparación
TW201002691A (en) Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
TW200413006A (en) Solid dispersions comprising a hygroscopic and/or deliquescent drug
CN103476400B (zh) 包含2-氨基-2-[2-(4-辛基苯基)乙基]丙-1,3-二醇的制剂
JP2014525463A5 (cg-RX-API-DMAC7.html)
EP1929997A1 (en) Oxcarbazepine formulations
WO2014025593A1 (en) Extended-release levetiracetam and method of preparation
JP2015071542A (ja) 固体分散体の製造方法
CN102139115A (zh) 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
HK1198430B (en) Formulations and dosage forms of oxidized phospholipids
NZ621710B2 (en) Formulations and dosage forms of oxidized phospholipids
WO2024043843A1 (en) Pharmaceutical compositions comprising cdca as active ingredient and relevant excipients
ES2734675T3 (es) Formulación de comprimido dispersable en agua que contiene deferasirox
CN107693516A (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
ES2733113T3 (es) Composición farmacéutica estable de una sal de vinorelbina soluble en agua
KR100958197B1 (ko) 올리스타트를 포함하는 약학적 조성물 및 이의 제조 방법
JP7847966B2 (ja) 医薬製剤およびその製造方法
JP2019514946A (ja) テモゾロミドを含む安定な抗腫瘍医薬組成物及び該組成物を調製する方法
KR101012903B1 (ko) 나노입자 형성을 이용하는 리세드로네이트 경질캡슐
WO2009004592A1 (en) Vancomycin compositions
TWI812891B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
TABLETS FORMULATION AND DEVELOPMENT OF

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Israel Modein

Patentee after: VASCULAR BIOGENICS LTD.

Address before: Israel Orr Yehuda

Patentee before: VASCULAR BIOGENICS LTD.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170609